Search Results - "Pearson, SA"

Refine Results
  1. 1

    De novo and recurrent metastatic breast cancer – A systematic review of population-level changes in survival since 1995 by Lord, SJ, Bahlmann, K, O'Connell, DL, Kiely, BE, Daniels, B, Pearson, SA, Beith, J, Bulsara, MK, Houssami, N

    Published in EClinicalMedicine (01-02-2022)
    “…Advances in breast cancer (BC) care have reduced mortality, but their impact on survival once diagnosed with metastasis is less well described. This systematic…”
    Get full text
    Journal Article
  2. 2

    An overview of the patterns of prescription opioid use, costs and related harms in Australia by Blanch, Bianca, Pearson, Sallie‐Anne, Haber, Paul S.

    Published in British journal of clinical pharmacology (01-11-2014)
    “…Aims To report Australian population trends in subsidized prescribed opioid use, total costs to the Australian government to subsidize these medicines and…”
    Get full text
    Journal Article
  3. 3

    Twenty‐five years of prescription opioid use in Australia: a whole‐of‐population analysis using pharmaceutical claims by Karanges, Emily A., Blanch, Bianca, Buckley, Nicholas A., Pearson, Sallie‐Anne

    Published in British journal of clinical pharmacology (01-07-2016)
    “…Aim The aim of this paper is to investigate 25‐year trends in community use of prescribed opioid analgesics in Australia, and to map these trends against major…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review by Parkinson, Bonny, Sermet, Catherine, Clement, Fiona, Crausaz, Steffan, Godman, Brian, Garner, Sarah, Choudhury, Moni, Pearson, Sallie-Anne, Viney, Rosalie, Lopert, Ruth, Elshaug, Adam G.

    Published in PharmacoEconomics (01-09-2015)
    “…Pharmaceutical expenditure has increased rapidly across many Organisation for Economic Cooperation and Development (OECD) countries over the past three…”
    Get full text
    Journal Article
  8. 8

    Trends in opioid utilisation in Australia, 2006‐2015: Insights from multiple metrics by Karanges, Emily A., Buckley, Nicholas A., Brett, Jonathan, Blanch, Bianca, Litchfield, Melisa, Degenhardt, Louisa, Pearson, Sallie‐Anne

    Published in Pharmacoepidemiology and drug safety (01-05-2018)
    “…Purpose Population‐based observational studies have documented global increases in opioid analgesic use. Many studies have used a single population‐adjusted…”
    Get full text
    Journal Article
  9. 9

    Post‐marketing studies of pharmaceutical opioid abuse‐deterrent formulations: a framework for research design and reporting by Peacock, Amy, Larance, Briony, Bruno, Raimondo, Pearson, Sallie‐Anne, Buckley, Nicholas A., Farrell, Michael, Degenhardt, Louisa

    Published in Addiction (Abingdon, England) (01-03-2019)
    “…Background and aims Opioid formulations with properties to deter abuse (abuse‐deterrent formulations; ADFs) have been developed as one response to the…”
    Get full text
    Journal Article
  10. 10

    To what extent do data from pharmaceutical claims under‐estimate opioid analgesic utilisation in Australia? by Gisev, Natasa, Pearson, Sallie‐Anne, Karanges, Emily A., Larance, Briony, Buckley, Nicholas A., Larney, Sarah, Dobbins, Timothy, Blanch, Bianca, Degenhardt, Louisa

    Published in Pharmacoepidemiology and drug safety (01-05-2018)
    “…Purpose Although pharmaceutical claims are an essential data source for pharmacoepidemiological studies, these data potentially under‐estimate opioid…”
    Get full text
    Journal Article
  11. 11

    A population-based study of transdermal fentanyl initiation in Australian clinical practice by Gisev, Natasa, Pearson, Sallie-Anne, Larance, Briony, Larney, Sarah, Blanch, Bianca, Degenhardt, Louisa

    Published in European journal of clinical pharmacology (01-03-2019)
    “…Purpose Although guidelines caution against initiation of transdermal (TD) fentanyl among those who are opioid naïve, there is concern that not all people…”
    Get full text
    Journal Article
  12. 12

    Effectiveness and framing of pharmaceutical opioid abuse‐deterrent formulations by Peacock, Amy, Larance, Briony, Bruno, Raimondo, Pearson, Sallie‐Anne, Buckley, Nicholas A., Farrell, Michael, Degenhardt, Louisa

    Published in Addiction (Abingdon, England) (01-03-2019)
    “…Abuse-deterrent formulations (ADFs) of pharmaceutical opioids have limited capacity to reduce extra-medical use and harm; their impact is likely restricted to…”
    Get full text
    Journal Article
  13. 13

    Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol by Gisev, Natasa, Pearson, Sallie-Anne, Dobbins, Timothy, Currow, David C, Blyth, Fiona, Larney, Sarah, Dunlop, Adrian, Mattick, Richard P, Wilson, Andrew, Degenhardt, Louisa

    Published in BMJ open (01-12-2018)
    “…IntroductionOpioid prescribing has increased 15-fold in Australia in the past two decades, alongside increases in a range of opioid-related harms such as…”
    Get full text
    Journal Article
  14. 14

    Demographic, social and lifestyle risk factors for cancer registry-notified cancer of unknown primary site (CUP) by Vajdic, C.M., Perez-Concha, O., Dobbins, T., Ward, R.L., Schaffer, A.L., van Leeuwen, M.T., Rhee, J.J., Laaksonen, M.A., Craigen, G., Pearson, S.A.

    Published in Cancer epidemiology (01-06-2019)
    “…•Older age and smoking increase risk of CUP independent of overall health.•Novel association between low educational attainment and increased risk of CUP.•No…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia by Schaffer, Andrea L., MBiostat PhD, Pearson, Sallie-Anne, PhD, Buckley, Nicholas A., MD, Degenhardt, Louisa, PhD, Larance, Briony, PhD, Dobbins, Timothy A., PhD, Cairns, Rose, PhD

    “…ABSTRACT BACKGROUND Australia introduced tamper-resistant controlled-release (CR) oxycodone in April 2014. We quantified the impact of the reformulation on…”
    Get full text
    Journal Article
  18. 18

    Increases in controlled‐release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population‐based study by Schaffer, Andrea L., Karanges, Emily A., Buckley, Nicholas A., Wilson, Andrew, Degenhardt, Louisa, Larance, Briony, Pearson, Sallie‐Anne

    Published in Pharmacoepidemiology and drug safety (01-01-2019)
    “…Purpose Despite increasing use of oxycodone/naloxone controlled‐release (CR) in Australia, little is known about how it has affected the overall oxycodone CR…”
    Get full text
    Journal Article
  19. 19
  20. 20